| Your Source for the Latest Patent Information |
User Functions Categories- All
- Announcements (5)
- In The News (609)
- OG Notice Links (306)
- Patents of the Day (468)
Archives- December 2007 (18)
- November 2007 (36)
- October 2007 (45)
- September 2007 (36)
- August 2007 (36)
- July 2007 (44)
- June 2007 (36)
- May 2007 (45)
- April 2007 (36)
- March 2007 (36)
- February 2007 (39)
- January 2007 (44)
- more...
Search Syndication Credits- powered by b2evo
- skin cloned from Movable Type
|
GEN-ERIC Patent News
Your Source for the Latest Patent Information
12/27/05
6,980,969 Methods and apparatus for allowing internet based purchases based on a temporary credit card number  12/27/05
6,981,216 Method and system for subpoena generation including time-dependent reverse number search  12/27/05
A federal judge refused to throw out a Gillette Co. patent-infringement lawsuit that seeks to stop Energizer Holdings Inc.'s Schick unit from selling the Quattro, a four-bladed razor. St. Louis-based Energizer paid $930 million for Schick early in 2003. Gillette, a Boston-based unit of Procter & Gamble Co., claims the Quattro infringes its patent for multibladed razors, according to a report by Bloomberg News. The patent covers the Gillette's best-selling Mach3 product line, which has three blades. U.S. District Judge Patti Saris this week rejected Schick's argument that the Gillette patent only covers three blades, not four. She refused to grant Schick's request for a ruling that there was no infringement of the patent. Gillette didn't ask for an immediate ruling that the Quattro did infringe the patent, so the case will proceed toward a trial. Posted by GEN-ERIC at 01:08:56 am into the following categories: In The News12/27/05
3M Company and 3M Innovative Properties Co., a wholly owned subsidiary of 3M, have won a favorable verdict in a patent infringement lawsuit filed in the United States District Court in Minnesota against Avery Dennison Corporation. On Wednesday afternoon, a jury in Minneapolis returned the verdict in favor of 3M, finding that 3M's United States Patent No. 5,897,930, which relates to release liners used in the manufacture and sale of pressure sensitive adhesives for large format graphics, is valid and has been infringed by Avery Dennison's sales of its EZ Series Fleet Marking Film. 3M's patented technology is used in the manufacture of 3M(TM) Controltac(TM) Plus Graphic Film with Comply(TM) Performance, a product that allows graphics to be applied more quickly and consistently, reducing wrinkles and bubbles throughout the application process. 3M's technology is especially effective for use in challenging applications, such as wrapping large fleet vehicles. Based on the favorable jury verdict, 3M will be asking the Court to enter a permanent injunction prohibiting further manufacture and sales of Avery Dennison's EZ Series Fleet Marking Film products. The amount of damages to be awarded to 3M as a result of Avery Dennison's infringement will be determined at an upcoming Court hearing. Posted by GEN-ERIC at 01:07:26 am into the following categories: In The News12/27/05
Ranbaxy Laboratories Limited announced today that it has entered into an agreement with Cephalon, Inc. to settle their pending patent infringement dispute in the United States related to PROVIGIL(R) (modafinil) Tablets [C-IV]. In connection with the settlement, Cephalon will grant Ranbaxy a non-exclusive royalty-bearing right to market and sell a generic version of PROVIGIL in the United States. Ranbaxy's license will become effective in October 2011 absence of a pediatric extension for PROVIGIL, which would delay the entry date by six months (to April, 2012). An earlier entry by Ranbaxy may occur based upon the entry of another generic version of PROVIGIL. The companies also agreed to a series of business arrangements related to modafinil. Specifically, Ranbaxy has agreed to grant to Cephalon a non-exclusive license, effective immediately, to certain of its worldwide intellectual property rights related to modafinil in exchange for milestone payments. Cephalon also has agreed to enter into certain arrangements with Ranbaxy related to Ranbaxy's supply of the active pharmaceutical ingredient modafinil. The terms of the agreement are confidential, and are subject to review by the U.S. Federal Trade Commission. Financial terms were not disclosed. Posted by GEN-ERIC at 01:06:35 am into the following categories: In The News12/27/05
Remy International, Inc., and Machinery Components, Inc. (MCI) today announced the settlement of a lawsuit in the U.S. District Court for the Southern District of Indiana in Indianapolis. Remy is the owner of two U.S. Patents for automotive alternators and had sued several parties, including MCI, accusing those parties of infringing its patents. Under the settlement, MCI has not admitted any liability for patent infringement, but the parties acknowledge that MCI has modified the design of its CS130 and 130D type alternators. Remy has agreed not to sue MCI for infringement of Remy's alternator patents by MCI's modified CS130 and CS-130D type alternators and has released MCI from claims of prior infringement of the two patents at issue. The settlement involved a payment from MCI to Remy. Posted by GEN-ERIC at 01:04:15 am into the following categories: In The News
|
Calendar| Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|
| << < | > >> | |||||
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 | |
LinksEmployment
USPTO
